Product Description
Mechanisms of Action: Exon 50 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Entrada Therapeutics
Company Location: BOSTON MA 02210
Company CEO: Dipal Doshi
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for ENTR-601-50](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Muscular Dystrophy, Duchenne
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|